Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 7/20 | 0.43 |
| ▸ | LIPG | Q9Y5X9 | 7/20 | 0.43 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.34 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.34 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.33 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19822182 | 1.00 | LPL (0.43) | LPLLIPGPRMT5WDR77IRAK4 | |
| SCHEMBL20225280 | 0.99 | LPL (0.42) | LPLLIPGPRMT5WDR77IRAK4 | |
| SCHEMBL20225287 | 0.99 | LPL (0.42) | LPLLIPGPRMT5WDR77IRAK4 | |
| SCHEMBL20225281 | 0.93 | LPL (0.43) | LPLLIPGPRMT5WDR77IRAK4 | |
| SCHEMBL29761248 | 0.90 | LPL (0.41) | LPLLIPGPRMT5WDR77IRAK4 | |
| SCHEMBL22289275 | 0.90 | LPL (0.41) | LPLLIPGPRMT5WDR77IRAK4 | |
| SCHEMBL16219708 | 0.88 | LPL (0.43) | LPLLIPGPRMT5WDR77IRAK4 | |
| SCHEMBL23930748 | 0.88 | LPL (0.39) | LPLLIPGPRMT5WDR77IRAK4 | |
| SCHEMBL29761250 | 0.88 | LPL (0.39) | LPLLIPGPRMT5WDR77IRAK4 | |
| SCHEMBL19869597 | 0.88 | LPL (0.39) | LPLLIPGPRMT5WDR77IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3512841-B1 | COMPOUNDS WITH SPIROBIFLUORENE-STRUCTURES | MERCK PATENT GMBH (DE) | 2023-04-26 | — | — | EP | disclosed |
| US-11447464-B2 | Compounds with spirobifluorene-structures | MERCK PATENT GMBH (DE) | 2022-09-20 | — | — | US | disclosed |
| US-20190194164-A1 | COMPOUNDS WITH SPIROBIFLUORENE-STRUCTURES | MERCK PATENT GMBH (DE) | 2019-06-27 | — | — | US | disclosed |
| US-10283716-B2 | Compound for organic electric element, organic electric element using the same, and electronic device comprising same | DUK SAN NEOLUX CO., LTD. (KR) | 2019-05-07 | — | — | US | disclosed |
| US-20180026187-A1 | NOVEL COMPOUND FOR ORGANIC ELECTRIC ELEMENT, ORGANIC ELECTRIC ELEMENT USING THE SAME, AND ELECTRONIC DEVICE COMPRISING SAME | DUK SAN NEOLUX CO., LTD. (KR) | 2018-01-25 | — | — | US | disclosed |
| US-20180026187-A1 | NOVEL COMPOUND FOR ORGANIC ELECTRIC ELEMENT, ORGANIC ELECTRIC ELEMENT USING THE SAME, AND ELECTRONIC DEVICE COMPRISING SAME | DUK SAN NEOLUX CO., LTD. (KR) | 2018-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180026187-A1 | NOVEL COMPOUND FOR ORGANIC ELECTRIC ELEMENT, ORGANIC ELECTRIC ELEMENT USING THE SAME, AND ELECTRONIC DEVICE COMPRISING SAME | EBPL, OR51E2, EML4 | LPL 2506/4885LIPG 1659/4885PRMT5 3888/4885 |
| US-11447464-B2 | Compounds with spirobifluorene-structures | SLCO1B3, SLCO4C1, SLCO1B1 | LPL 4408/4885LIPG 3966/4885PRMT5 4276/4885 |
| US-10283716-B2 | Compound for organic electric element, organic electric element using the same, and electronic device comprising same | EBPL, OR51E2, EML4 | LPL 2503/4885LIPG 1730/4885PRMT5 3754/4885 |
| US-20190194164-A1 | COMPOUNDS WITH SPIROBIFLUORENE-STRUCTURES | SLCO1B3, SLCO4C1, SLCO1B1 | LPL 4408/4885LIPG 3966/4885PRMT5 4276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.